Atlanta, GA Clinical Trials Report — April 2026

April 2026 brings a critical window for Atlantans considering participation in clinical trials, especially with 92 studies slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 13 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Act Now: Trials Nearing Enrollment Close

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, cardiovascular health, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart failure (4 trials)
• Gastric cancer (3 trials)
• Advanced breast cancer (3 trials)
• Stage IV lung cancer AJCC V8 (2 trials)
• Primary peritoneal cancer (2 trials)
• Triple negative breast cancer (2 trials)
• Idiopathic hypersomnia (2 trials)
• Fallopian tube cancer (2 trials)
• Breast cancer (2 trials)
• Major depressive disorder (2 trials)

Overall, Atlanta, GA, continues to be a significant hub for medical research, with 1,390 clinical trials currently recruiting across 552 research facilities. This month, 12 new trials opened, a slight decrease from the 14 trials that launched in March 2026.

New Opportunities in Atlanta Research

April brings several high-profile new trials to Atlanta, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Boehringer Ingelheim is sponsoring NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study is open to adults with advanced extrapulmonary neuroendocrine cancer, aiming to find out if obrixtamig plus standard chemotherapy improves survival.
• Eccogene is initiating NCT07505303, "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial." This Phase 2 study, aiming for 160 participants, will evaluate the effect of oral ECC4703 on body weight reduction and liver fat content in individuals with adult obesity.
• Carelon Research is leading NCT07525843, "A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study." This study, designed for 390 participants, aims to learn if a 5-week online program can help teens with congenital heart disease improve their ability to handle stress.
• UNC Lineberger Comprehensive Cancer Center is sponsoring NCT07520188, "C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States." This project aims to improve access to cervical cancer screening among women with HIV.
• RTI International is launching NCT07527988, "Safer Drinking Spaces Study." This study, seeking 3,180 participants, will evaluate active bystander training provided to staff at alcohol-serving establishments to improve safety.

New trials this month are exploring a range of conditions, including acute myeloid leukemia, adolescent congenital heart disease, adult obesity, alcohol misuse, bystander intervention, cervical cancer, cervical precancer, HIV infections, and a study specifically for healthy volunteers. Drug trials account for 5 of the new studies, with 6 behavioral trials and 1 device trial also opening.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research. 6 of the 12 new trials launched this month are actively seeking healthy volunteers. Across Atlanta, a total of 121 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Atlanta's Leading Research Facilities

Atlanta is home to some of Georgia's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Emory University (192 trials)
• Emory University Hospital/Winship Cancer Institute (126 trials)
• Emory University Hospital Midtown (118 trials)
• Emory University Hospital (87 trials)
• Emory Saint Joseph's Hospital (84 trials)
• Children's Healthcare of Atlanta (53 trials)
• Grady Health System (51 trials)
• Northside Hospital (46 trials)
• Research Site (45 trials)
• Emory University School of Medicine (41 trials)
• Children's Healthcare of Atlanta - Arthur M Blank Hospital (37 trials)
• Winship Cancer Institute of Emory University (30 trials)

These institutions offer a broad spectrum of research, from oncology at Emory's Winship Cancer Institute to pediatric care at Children's Healthcare of Atlanta, and general medical research across the Emory University hospital system and Grady Health System.

Broadening Your Search: Nearby Options

While Atlanta offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Georgia. Cities with active trials include Decatur (2 trials), Athens (1 trial), Augusta (1 trial), Alpharetta (1 trial), Dallas (1 trial), Sandy Springs (1 trial), and Cordele (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 12 new trials launched this month, 3 include children, and 8 include older adults, ensuring that these populations have ample opportunity to contribute to medical science. Academic institutions, particularly Emory University and Georgia State University, continue to play a vital role in Atlanta's research ecosystem, sponsoring many new trials alongside industry leaders like Incyte Corporation and Eccogene, and government-funded research from the National Institute of Allergy and Infectious Diseases (NIAID).

As we move further into spring, Atlanta's robust research community will continue to drive medical innovation, with ongoing enrollment in these significant Phase 2 and Phase 3 trials and the exploration of new therapeutic strategies.